



(11) **EP 1 905 830 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 15/12 (2006.01) **C12N 15/62** (2006.01)
C07K 14/47 (2006.01) **A61K 38/17** (2006.01)

(48) Corrigendum issued on:
11.04.2012 Bulletin 2012/15

(45) Date of publication and mention
of the grant of the patent:
07.03.2012 Bulletin 2012/10

(21) Application number: **07021046.3**

(22) Date of filing: **12.10.2000**

(54) **Cell-permeable peptide inhibitors of the JNK signal transduction pathway**

Zelldurchlässige Peptidhemmer des JNK-Signaltransduktionsweges

Inhibiteurs peptidiques à perméabilité cellulaire du processus de transduction du signal de JNK

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **12.10.1999 US 158774 P**
14.02.2000 US 503954

(43) Date of publication of application:
02.04.2008 Bulletin 2008/14

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
00969730.1 / 1 303 600

(73) Proprietor: **Xigen S.A.**
1066 Epalinges (CH)

(72) Inventor: **Bonny, Christophe**
1006 Lausanne (CH)

(74) Representative: **Graf von Stosch, Andreas et al**
Graf von Stosch
Patentanwalts-gesellschaft mbH
Prinzregentenstrasse 22
80538 München (DE)

(56) References cited:

EP-A- 0 897 002 WO-A-94/04686
WO-A-98/44106 WO-A-98/49188

- **DICKENS M ET AL.:** "A cytoplasmic inhibitor of the JNK signal transduction pathway" **SCIENCE**, vol. 277, no. 5326, 1 August 1997 (1997-08-01), pages 693-696, XP002172257
- **YASUDA J ET AL.:** "The JIP group of mitogen-activated protein kinase scaffold proteins" **MOLECULAR AND CELLULAR BIOLOGY**, vol. 19, no. 10, October 1999 (1999-10), pages 7245-7254, XP002172259
- **BONNY C ET AL.:** "IB1, a JIP-1-related nuclear protein present in insulin-secreting cells" **JOURNAL OF BIOLOGICAL CHEMISTRY**, vol. 273, no. 4, 23 January 1998 (1998-01-23), pages 1843-1846, XP002172258
- **VIVÈS E ET AL.:** "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus." **JOURNAL OF BIOLOGICAL CHEMISTRY**, vol. 272, no. 25, 20 June 1997 (1997-06-20), pages 16010-16017, XP002172260
- **BONNY C ET AL.:** "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death." **DIABETES**, vol. 50, no. 1, January 2001 (2001-01), pages 77-82, XP002172261

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 905 830 B8